Haematological problems in intensive care: recent advances and developments

There have been significant changes in the management of several haematological conditions over the last decade. This article focuses on three key areas – chimeric antigen receptor (CAR) T-cell therapy, haemophagocytic lymphohistiocytosis (HLH) and thrombotic thrombocytopenic purpura (TTP) – and the implications these areas have for clinicians working in intensive care medicine. There is particular focus on CAR T-cell therapy given its novel nature and implications for both critical care practice and resource utilization.